Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.

Pellett S, Bradshaw M, Tepp WH, Pier CL, Whitemarsh RCM, Chen C, Barbieri JT, Johnson EA.

mBio. 2018 Mar 27;9(2). pii: e00089-18. doi: 10.1128/mBio.00089-18.

2.

Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain.

Pellett S, Tepp WH, Bradshaw M, Kalb SR, Dykes JK, Lin G, Nawrocki EM, Pier CL, Barr JR, Maslanka SE, Johnson EA.

mSphere. 2016 Feb 24;1(1). pii: e00100-15. doi: 10.1128/mSphere.00100-15. eCollection 2016 Jan-Feb.

3.

Human Induced Pluripotent Stem Cell Derived Neuronal Cells Cultured on Chemically-Defined Hydrogels for Sensitive In Vitro Detection of Botulinum Neurotoxin.

Pellett S, Schwartz MP, Tepp WH, Josephson R, Scherf JM, Pier CL, Thomson JA, Murphy WL, Johnson EA.

Sci Rep. 2015 Sep 28;5:14566. doi: 10.1038/srep14566.

4.

A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.

Maslanka SE, L├║quez C, Dykes JK, Tepp WH, Pier CL, Pellett S, Raphael BH, Kalb SR, Barr JR, Rao A, Johnson EA.

J Infect Dis. 2016 Feb 1;213(3):379-85. doi: 10.1093/infdis/jiv327. Epub 2015 Jun 10.

5.

Activity of botulinum neurotoxin type D (strain 1873) in human neurons.

Pellett S, Tepp WH, Scherf JM, Pier CL, Johnson EA.

Toxicon. 2015 Jul;101:63-9. doi: 10.1016/j.toxicon.2015.04.015. Epub 2015 Apr 30.

6.

Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro.

Whitemarsh RC, Tepp WH, Bradshaw M, Lin G, Pier CL, Scherf JM, Johnson EA, Pellett S.

Infect Immun. 2013 Oct;81(10):3894-902. doi: 10.1128/IAI.00536-13. Epub 2013 Aug 5.

7.

Model for studying Clostridium botulinum neurotoxin using differentiated motor neuron-like NG108-15 cells.

Whitemarsh RC, Pier CL, Tepp WH, Pellett S, Johnson EA.

Biochem Biophys Res Commun. 2012 Oct 19;427(2):426-30. doi: 10.1016/j.bbrc.2012.09.082. Epub 2012 Sep 20.

8.

Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells.

Pellett S, Du ZW, Pier CL, Tepp WH, Zhang SC, Johnson EA.

Biochem Biophys Res Commun. 2011 Jan 7;404(1):388-92. doi: 10.1016/j.bbrc.2010.11.128. Epub 2010 Dec 3.

9.

Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1.

Pier CL, Chen C, Tepp WH, Lin G, Janda KD, Barbieri JT, Pellett S, Johnson EA.

FEBS Lett. 2011 Jan 3;585(1):199-206. doi: 10.1016/j.febslet.2010.11.045. Epub 2010 Nov 30.

10.

Expression of the Clostridium botulinum A2 neurotoxin gene cluster proteins and characterization of the A2 complex.

Lin G, Tepp WH, Pier CL, Jacobson MJ, Johnson EA.

Appl Environ Microbiol. 2010 Jan;76(1):40-7. doi: 10.1128/AEM.01882-09. Epub 2009 Nov 13.

11.

Subunit vaccine against the seven serotypes of botulism.

Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, Barbieri JT.

Infect Immun. 2008 Mar;76(3):1314-8. Epub 2007 Dec 10.

12.

Recombinant holotoxoid vaccine against botulism.

Pier CL, Tepp WH, Bradshaw M, Johnson EA, Barbieri JT, Baldwin MR.

Infect Immun. 2008 Jan;76(1):437-42. Epub 2007 Oct 29.

13.

Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.

Baldwin MR, Tepp WH, Pier CL, Bradshaw M, Ho M, Wilson BA, Fritz RB, Johnson EA, Barbieri JT.

Infect Immun. 2005 Oct;73(10):6998-7005.

Supplemental Content

Support Center